Threshold Pharmaceuticals Inc. (NASDAQ:THLD) belonging to the Medical sector which declined -12.32% and closed its last trading session at $0.6.
The company reported its last EPS on 6/30/2016 and is expected to report its next EPS on 11/7/2016. Currently, the stock has a 1 Year Price Target of $1.25.
The consensus recommendation, according to Zacks Investment research, is 2.5. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 2.5 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2.5 and 2.5 respectively.
Threshold Pharmaceuticals Inc. on 6/30/2016 reported its EPS as $-0.1 with the analysts projecting the EPS of the stock as $-0.1. The company beat the analyst EPS Estimate with the difference of $0. This shows a surprise factor of 0%.
Many analysts have provided their estimated foresights on Threshold Pharmaceuticals Inc. Earnings, with 3 analysts believing the company would generate an Average Estimate of $-0.09. Whereas they predicted High and Low Earnings Estimate as $-0.08 and $-0.09 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.09.
The Company got Initiated by H.C. Wainwright on 5-Sep-14 to Buy.
Insider Trades for Threshold Pharmaceuticals Inc. show that the latest trade was made on 29 Feb 2016 where BIRD JEFFREY W, the Director completed a transaction type “Buy” in which 96010 shares were traded at a price of $0.
2 analysts projected Price Targets for Threshold Pharmaceuticals Inc. The analysts believe that the company stock price could grow as high as $2. The Low Price target projection by analysts is $0.5 and the Mean Price Target is $1.25.
Threshold Pharmaceuticals Inc. (NASDAQ:THLD) has the market capitalization of $74.21 Million. The company rocked its 52-Week High of $4.44 on Nov 9, 2015 and touched its 52-Week Low of $0.21 on Feb 24, 2016. The stock has Return on Assets (ROA) of 99.7 percent. Return on Equity (ROE) stands at 271.2% and Return on Investment (ROI) of 66 percent.
The stock is currently showing YTD performance of 24.21 Percent. The company has Beta Value of 3.78 and ATR value of 0.14. The Weekly and Monthly Volatility stands at 16.40% and 10.51%.
Threshold is focused on the discovery, development, and commercialization of small molecule therapeutics based on Metabolic Targeting. This approach targets abnormal glucose metabolism – a fundamental property of most solid tumors and other diseases. The company’s initial focus is the treatment of cancer and benign prostatic hyperplasia, a disease characterized by overgrowth of the prostate.